November 7, 2023 04:34 AM EST

Vertex discontinues a PhII rare disease drug, sets early 2024 timeline for pivotal non-opioid pain pill readout

Andrew Dunn

Senior Biopharma Correspondent

Lei Lei Wu

News Reporter

Side effects have led Vertex Pharmaceuticals to stop work on another Phase II drug candidate to treat a rare genetic disease called alpha-1 antitrypsin defiency …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vertex discontinues a PhII rare disease drug, sets early 2024 timeline for pivotal non-opioid pain pill readout

Andrew Dunn

Senior Biopharma Correspondent

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Ver­tex dis­con­tin­ues a PhII rare dis­ease drug, sets ear­ly 2024 time­line for piv­otal non-opi­oid pain pill read­out

Senior Biopharma Correspondent

News Reporter

Sign up to read this article for free.

Vertex discontinues a PhII rare disease drug, sets early 2024 timeline for pivotal non-opioid pain pill readout